In a patient taking losartan (angiotensin receptor blocker), will a ketorolac (Toradol) injection and a five‑day course of oral NSAID tablets raise his blood pressure?

Yes, Ketorolac Can Raise Blood Pressure in Patients on Losartan

A ketorolac injection and 5-day course of oral NSAIDs can indeed elevate blood pressure in a patient taking losartan (an ARB), and this interaction is clinically significant. NSAIDs, including ketorolac, are well-documented to attenuate the antihypertensive effects of angiotensin receptor blockers and can independently raise blood pressure through multiple mechanisms 1, 2.

The Mechanism of the Interaction

NSAIDs interfere with blood pressure control through several pathways:

• Prostaglandin inhibition: NSAIDs block cyclooxygenase (COX) enzymes, reducing vasodilatory prostaglandins that normally help maintain lower blood pressure and support the action of antihypertensive medications 3, 4
• Sodium and water retention: This occurs through renal mechanisms, leading to volume expansion 1, 2
• Reduced efficacy of ARBs: The antihypertensive effect of losartan specifically depends partly on prostaglandin-mediated vasodilation, which NSAIDs counteract 5, 4

The Evidence for This Interaction

A direct study of this exact interaction showed that indomethacin (another NSAID) significantly attenuated the blood pressure-lowering effect of losartan by 2.2 mmHg over 24 hours 5. While this may seem modest, it represents a meaningful reduction in the drug's effectiveness.

Meta-analyses demonstrate that NSAIDs cause blood pressure elevations averaging 3-5 mmHg in hypertensive patients on antihypertensive therapy 6, 3. This effect is:

• Most pronounced in patients already taking antihypertensive medications (like your patient on losartan)
• Present with both non-selective NSAIDs and COX-2 inhibitors
• Clinically significant because even a 5-6 mmHg sustained increase in diastolic BP is associated with a 67% increase in stroke risk 7

Ketorolac-Specific Considerations

Ketorolac is among the more potent NSAIDs and carries particular risks 8, 2:

• The FDA label for ketorolac specifically warns about edema, which reflects sodium retention that can elevate blood pressure 8
• Treatment duration is explicitly limited to 5 days maximum due to cumulative adverse effects 8
• Ketorolac can cause acute kidney injury, especially in patients with any degree of renal impairment, which would further compromise blood pressure control 9

Clinical Recommendations

Monitor blood pressure during and after NSAID use 2, 10:

• Check BP before starting ketorolac
• Recheck BP during the 5-day course and shortly after completion
• Be alert for BP elevations of 5+ mmHg systolic

Consider the patient's cardiovascular risk profile 1, 10:

• Patients with controlled hypertension on ARBs like losartan are at higher risk for NSAID-induced BP elevation
• If the patient has additional cardiovascular risk factors (diabetes, CKD, prior MI/stroke), the interaction becomes more concerning

Assess renal function 2, 10:

• NSAIDs combined with ARBs can impair renal function
• Both drug classes affect intrarenal hemodynamics
• Monitor for worsening renal function, which would further elevate BP

Common Pitfalls to Avoid

1. Assuming short-term use is safe: Even 5 days of ketorolac can produce measurable BP effects 5, 3

2. Not monitoring BP: The interaction is predictable enough that proactive monitoring is warranted rather than waiting for symptoms 2, 10

3. Ignoring the cumulative effect: If the patient is already on losartan, their BP control may be marginal, and even a 3-5 mmHg increase could push them into poorly controlled hypertension 11

Alternative Approaches

If pain control is needed but BP elevation is a concern 1:

• Acetaminophen is the safest first-line option (no effect on BP)
• Short-acting opioids for severe pain (though with their own risks)
• Topical NSAIDs for localized pain (minimal systemic absorption)

The evidence consistently shows that all NSAIDs, including ketorolac, can antagonize the blood pressure-lowering effects of ARBs like losartan 5, 4, 10. While a single injection plus 5 days of tablets may not cause dramatic hypertension in every patient, it represents a real and measurable risk that warrants monitoring and consideration of alternatives when feasible.